Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018

世界のバイオシミラー市場予測

◆タイトル:Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018
◆商品コード:MAM40116036
◆調査・発行会社:MarketsandMarkets
◆発行日:2013年11月
◆ページ数:320
◆レポート形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:世界
◆販売価格オプション(消費税別)
Single userUSD5,650 ⇒換算¥638,450見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥751,450見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"世界のバイオシミラー市場予測"について調査・分析し、イントロダクション、エグゼクティブサマリー、プレミアムインサイト、市場概観、市場の成長要因、阻害要因、市場の機会と課題、産業動向、市場環境分析、市場の動態、パイプライン分析、製品別分析、用途別分析、地域別分析、市場規模及び予測、競争状況、市場シェア分析、新製品発売、主要企業(ベンダー)分析等の情報をお届けいたします。

The biosimilar products market is segmented into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant non-glycosylated proteins market is further segmented as insulin, granulocyte colony-stimulating factor (G-CSF), interferons, and human growth hormone; whereas the recombinant glycosylated proteins market is further broken down into erythropoietin, monoclonal antibodies, and follitropin. Calcitonin and glucagon are considered in the recombinant peptides market. The recombinant glycosylated proteins segment is expected to witness the highest growth due to the increased demand for monoclonal antibodies in the treatment for cancer (oncology), autoimmune disorders, blood disorders, and infectious diseases. Oncology will be the fastest-growing segment and currently accounts for a 25% market share in the global market in 2013. Following monoclonal antibodies, biosimilars of insulin will be the fastest-growing products and are estimated to grow at a CAGR of 35.6% from 2013 to 2018. The growth is attributed to the rise in incidences of diabetes; ongoing patent expirations of biologic drugs such as Lantus, Humalog, and Novorapid; and the cost effectiveness of the biosimilars of insulin.

Other notable driving factors for the global market include increasing number of off-patented drugs, positive outcome in the ongoing clinical trials, and rising demand for biosimilars in different therapeutic applications such as rheumatoid arthritis and blood disorders.

Market dynamics analysis has identified that rising budgetary pressures to reduce healthcare expenditures, increasing aging population, growing demand for cost-effective alternatives, rising incidences of various diseases, and conducive government initiatives are significant factors propelling the market in the forecast period (2013 to 2018). On the other hand, stringent regulatory environment, high manufacturing complexities and costs, and high-entry barriers are considered to hinder the market growth. Additionally, the different terminology and guidelines for biosimilars across regions will further burden the biosimilars industry. Generic versions of biologic drugs approved under the European Medical Agency (EMA) regulatory pathway and section 351K of the U.S. FDA are considered as biosimilars. In the U.S., biosimilars are also known as follow-on-proteins and have been approved under section 501(b), whereas in Canada, biosimilars are called Substituent Entry Biologics (SEB).

Geographic analysis reveals that Europe is the largest contributor to the global market. Asia-Pacific (China, India, and South Korea), North America (U.S.), and Latin America (Brazil) are poised to grow at high double-digit rates.

The global market is highly consolidated with the top three players, namely, Sandoz (Germany), Hospira (U.S.), and Teva (Israel) accounting for approximately 90% of the market share. Other notable players in the market include Dr. Reddy’s Laboratories (India), Biocon Ltd. (India), Mylan (U.S.), Biopartners (Switzerland), Amgen (U.S.), and IntasBiopharmaceutical Ltd. (India).

From an insight perspective, this research report focuses on the qualitative data, market size, share, and growth of various segments and sub-segments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis, such as market dynamics (drivers, restraints, opportunities, and threats), value chain, biosimilar pipeline analysis, porter’s five forces analysis, regulations, and reimbursement challenges across geographies. The report also offers market shares, sizes, and related growth of various segments of the industry. It also focuses on the emerging and high-growth segments of biosimilars (monoclonal antibodies and insulin), high-growth regions, countries, and the initiatives of their respective governments.

The grey area, while estimating the market size, is the different terminologies of biosimilars as well as different regulatory environments in different regions. The different terminologies considered for this study are Follow-on Proteins (U.S. and Japan), Subsequent Entry Biologics (Canada), Biosimilars (Europe and Australia), and Similar Biologics (Asia excluding Japan). North America and Europe have a stringent regulatory environment, whereas in comparison, Asia and RoW have a less stringent regulatory environment for approving biosimilars in the market.

The competitive landscape covers the growth strategies adopted by the industry players in the last three years. The company profiles comprise of the basic views on the key players in the biosimilars market and the product portfolios, developments, and strategies adopted to maintain and increase their market shares in the near future. The above-mentioned market research data, current market size, and forecast of future trends will help the key players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Scope of the Report
The study covers the revenue market of recombinant glycosylated proteins, recombinant non-glycosylated proteins, and recombinant peptides—the three major drug classes of the market. The sales revenue of each biosimilar drug was considered to estimate the global market. The market revenue for each therapeutic area was calculated based on the type of drugs used to treat a particular disease. The market share of the key players involved in manufacturing and commercializing biosimilar products was considered to estimate the market.

The following different terminologies of biosimilars are considered while estimating the market size:

Biosimilars Market

In North America, follow-on biologic products that were approved under section 501(b) of the regulatory pathway are considered while estimating the market size, while in Asia-Pacific; similar biologic products are considered to estimate the market size.

The sales revenue of both biogenerics and biobetters are not in the scope of this report. Biogenerics are the generic versions of biologic drugs that might not be the exact copy of biologics but a few variations are prevalent in these drugs with regards to efficiency, safety, and potency. Biobetters, on the other hand, are improvised versions of biologic drugs and are not similar or identical to biologic drugs in terms of efficacy, safety, and quality.

This research report categorizes the market into the following segments:

Global Biosimilars Market, by Product:
Recombinant Non-glycosylated Proteins
Insulin
Human Growth Hormone
Granulocyte Colony-stimulating Factor (G-CSF)
Interferons
Recombinant Glycosylated Proteins
Erythropoietin
Monoclonal Antibodies
Follitropin
Recombinant Peptides
Glucagon
Calcitonin
Global Biosimilars Market, by Service:
Contract Manufacturing Organizations (CMO)
Contract Research Organizations(CRO)
Others (Bioinformatics and Sales & Marketing Services)
Global Biosimilars Market, by Application:
Oncology
Blood Disorders
Chronic & Autoimmune Diseases
Growth Hormone Deficiency
Infectious Diseases
Others
Global Biosimilars Market, by Geography:
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Rest of Europe (RoE)
Asia-Pacific
China
Japan
South Korea
India
Rest of Asia-Pacific(RoAP)
Rest of World
Latin America
Africa
Middle East

【レポートの目次】

1 Introduction (Page No. – 26)
1.1 Objectives Of The Study
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Market Scope
1.6 Research Methodology
1.6.1 Market Size Estimation And Data Triangulation
1.6.2 Market Share
1.6.3 Key Data Points From Secondary Sources
1.6.4 Key Data Points From Primary Sources
1.6.5 Assumptions

2 Executive Summary (Page No. – 38)

3 Premium Insights (Page No. – 42)
3.1 Biosimilars Market Vs. Biologic Market
3.2 Global Biosimilars Market
3.2.1 Market Dynamics
3.2.2 Product Market
3.2.3 Application Market
3.3 Geographic Analysis, By Country
3.4 Market Share Analysis

4 Market Overview (Page No. – 49)
4.1 Introduction
4.2 Evolution
4.3 Market Segmentation
4.4 Market Dynamics
4.4.1 Drivers
4.4.1.1 Growing Pressure To Cut Healthcare Expenditure, An Impetus To The Demand Of Biosimilars
4.4.1.2 Off-Patent Biologic Products To Boost The Biosimilars Market
4.4.1.3 Rise In Aging Population Triggers The Incidences Of Chronic Disorders And Thus Boosts The Biosimilars Market
4.4.1.4 Growing Demand For Biosimilars Drugs Due To Their Cost Effectiveness
4.4.1.5 Rising Incidences Of Various Diseases To Boost The Biosimilars Market
4.4.1.6 Strategic Collaborations Lead To Increased Productivity And Clinical Trial Activities For Biosimilars
4.4.1.7 Government Support And Initiatives Propel The Biosimilars Market
4.4.2 Restraints
4.4.2.1 High Manufacturing Complexities And Costs, A Significant Entry Barrier For Companies
4.4.2.2 Stringent Regulatory Requirements In Countries To Adversely Affect Investments In Biosimilars
4.4.2.3 Innovative Strategies By Biologic Drug Manufacturers To Restrict Entry Into The Biosimilars Market
4.4.3 Opportunities
4.4.3.1 Emerging Countries
4.4.3.2 Untapped Indications
4.4.4 Challenges
4.4.4.1 Requirement Of Complex Infrastructure For Manufacturing As Well As Extensive Clinical Trials For Obtaining Approval
4.4.4.2 Bulk Production To Meet Market Demand Is A Challenge For Smaller Manufacturers
4.5 Winning Imperatives
4.5.1 Partnerships & Agreements To Gain Competitive Advantage
4.5.2 Sandoz’s In-House Capabilities Made It The Global Leader
4.6 Burning Issues
4.6.1 Opportunities For New Entrants In The Biosimilars Market
4.6.2 Product Withdrawals Provide Significant Opportunities For New Entrants
4.6.3 Termination Of Joint Ventures Allows Companies To Focus On Core Competencies
4.6.4 Discontinuation Of Patent By Roche Provides Opportunities To Other Players
4.7 Biosimilars Pipeline Analysis
4.7.1 About 50 Biosimilars Of Monoclonal Antibody In The Pipeline

5 Industry Analysis (Page No. – 82)
5.1 Introduction
5.2 Research & Development Investment Analysis
5.3 Industry Trend Analysis
5.3.1 Forthcoming Patent Expirations
5.3.2 Manufacturing Agreement
5.4 Porter’s Five Forces Analysis
5.4.1 Threat Of New Entrants
5.4.2 Threat Of Substitutes
5.4.3 Competitor Rivalry
5.4.4 Bargaining Power Of Suppliers
5.4.5 Bargaining Power Of Buyers

6 Global Biosimilars Market, By Product (Page No. – 90)
6.1 Introduction
6.1.1 Biosimilars Demand To Grow Owing To High Efficacies & Low Prices
6.2 Recombinant Non-Glycosylated Proteins
6.2.1 Insulin Biosimilars Will Drive The Recombinant Non-Glycosylated Proteins Segment
6.2.2 Insulin
6.2.2.1 Insulin Glargine, Lispro, And Aspart Will Go Off-Patent In 2014
6.2.3 Recombinant Human Growth Hormone (RHGH)
6.2.4 Granulocyte Colony-Stimulating Factor (Filgrastim)
6.2.4.1 Strong Biosimilars Pipeline To Boost The Filgrastim Market
6.2.5 Interferons
6.2.5.1 Biosimilars Of Interferon Available Only In Asia-Pacific And Row Regions Due To Less Stringent Regulatory Pathway
6.3 Recombinant Glycosylated Proteins
6.3.1 Erythropoietin (EPO)
6.3.1.1 Cost Effectiveness Of Epo Biosimilars, One Of The Major Driving Factors
6.3.2 Monoclonal Antibodies (MAB)
6.3.2.1 Monoclonal Antibodies Market, A Lucrative Opportunity For Companies
6.3.3 Follitropin
6.3.3.1 New Biosimilars Of Follitropin ‘Ovaleap’ Received Marketing Authorization In Europe In 2014
6.4 Recombinant Peptides
6.4.1 Glucagon
6.4.1.1 Glucagen, The First Fop Approved In U.S.
6.4.2 Calcitonin
6.4.2.1 U.S. Fda Does Not Support Miacalcin As A Treatment For Osteoporosis

7 Global Biosimilars Market, By Application (Page No. – 122)
7.1 Introduction
7.2 Oncology
7.2.1 Growing Cost Burden Of Cancer Will Stimulate The Demand For Mabs & Filgrastim
7.3 Blood Disorders
7.3.1 Rise In Incidences Of Anemia, Leukemia, Myeloma & Lymphoma Will Enhance The Need For Biosimilars
7.4 Chronic And Autoimmune Diseases
7.4.1 Monoclonal Antibodies To Boost The Application Of Biosimilars In Autoimmune Diseases
7.5 Growth Hormone Deficiency
7.5.1 About 10,000 New Patients Are Diagnosed Annually With Growth Hormonal Disorders
7.6 Infectious Diseases
7.6.1 Growing Cases Of Hepatitis, A Boost For The Interferon Biosimilars Market
7.7 Others (Female Infertility, Hypoglycaemia, Myocardial Infarction, Postmenopausal Osteoporosis & Chronic Kidney Failure)

8 Global Biosimilars Service Market (Page No. – 138)
8.1 Introduction
8.1.1 R&D And Manufacturing Issues Provide Significant Opportunities To CRO & CMO
8.2 Contract Manufacturing Organizations
8.2.1 CMO Provide Considerable Opportunities To Companies Planning To Enter Biosimilars Market
8.3 Contract Research Organizations
8.3.1 Lack Of Expertise With The Biosimilars Players, A Prospect For Cro
8.4 Others (Non-Clinical & Bioinformatics)

9 Geographic Analysis (Page No. – 148)
9.1 Introduction
9.1.1 Europe Dominates The Global Biosimilars Market Due To Its Well Defined Regulatory Guidelines
9.2 North America
9.2.1 Rise In Pressure To Cut Healthcare Cost & A Leading Biologic Market Will Increase The Demand For Low Priced Biosimilars
9.2.2 Regulatory Outlook
9.2.2.1 U.S.
9.2.2.2 Canada
9.2.3 Market Analysis
9.2.3.1 U.S.
9.2.3.1.1 Financial Support By U.S. Government To FDA For Review Of Biosimilars Will Add Significant Growth To Biosimilars Industry
9.2.3.2 Canada
9.3 Europe
9.3.1 Europe Is The Pioneer For The Development Of Biosimilars
9.3.2 Regulatory Outlook
9.3.3 Market Analysis
9.3.3.1 U.K.
9.3.3.1.1 Well-Developed Generics Market & Growing Pressure To Decrease Drug Prices To Drive The Biosimilars Market
9.3.3.2 Germany
9.3.3.2.1 Reference Pricing System Of Germany Leads To Faster Adoption Of Biosimilars
9.3.3.3 France
9.3.3.3.1 Biosimilars Not Considered As Generic Drugs & Are Excluded From The French Substitution List
9.3.3.4 Spain
9.3.3.4.1 Effect Of Recession On Branded Drugs Will Shift The Market Towards Biosimilars Drugs
9.3.3.5 Italy
9.3.3.5.1 Adoption Of Biosimilars Low Compared To Branded Versions
9.3.3.6 Rest Of Europe (ROE)
9.3.3.6.1 Substitution Status Varies In Different Countries
9.3.3.6.2 Reference Pricing System Of Denmark Will Proliferate The Biosimilars Market
9.4 Asia-Pacific
9.4.1 APAC, A Blue-Eyed Market For Investors In Biosimilars Owing To Less Stringent Regulatory Pathway
9.4.2 Growing Medical Tourism & Low Manufacturing Cost Will Propel The Biosimilars Market
9.4.3 Regulatory Outlook
9.4.3.1 China
9.4.3.2 India
9.4.3.3 Japan
9.4.3.4 South Korea
9.4.4 Market Analysis
9.4.4.1 China
9.4.4.1.1 Lack Of Government Regulation & Low Ip Protection For Biologic Compounds Will Drive The Biosimilars Market
9.4.4.2 India
9.4.4.2.1 Semi-Regulatory Environment For Approving Similar Biologic Drugs Propels The Biosimilars Market
9.4.4.3 Japan
9.4.4.4 South Korea
9.4.4.4.1 Government Support & Strong Biosimilar Pipeline, An Impetus To The Biosimilars Market
9.4.4.5 Rest Of Asia-Pacific (ROAP)
9.4.4.5.1 Australia & Malaysia To Aggressively Promote The Adoption Of Biosimilars
9.5 Rest Of The World (ROW)
9.5.1 Latam Provides High Growth Opportunities For Biosimilars Player
9.5.2 Regulatory Outlook
9.5.2.1 Brazil
9.5.2.2 Mexico
9.5.2.3 Argentina
9.5.2.4 Saudi Arabia
9.5.3 Market Analysis
9.5.3.1 Latin America
9.5.3.1.1 Strong Economic Condition & Government Support Will Strengthen The Biosimilar Industry In Brazil
9.5.3.2 Africa
9.5.3.3 Middle East

10 Competitive Landscape (Page No. – 218)
10.1 Introduction
10.1.1 Agreements & Partnerships Was The Key Strategy Adopted By Biosimilar Players
10.2 Market Share Analysis
10.3 Agreements, Joint Ventures, Partnerships, & Collaborations
10.4 Acquisitions
10.5 New Product Launches
10.6 Others (Regulatory Approvals)

11 Company Profiles (Overview, Financials, Products & Services, Strategy, & Developments)* (Page No. – 238)
11.1 Actavis, Inc.
11.2 Amgen, Inc.
11.3 Biocon Ltd.
11.4 Celltrion, Inc.
11.5 Cipla Ltd.
11.6 Dr. Reddy’s Laboratories Ltd.
11.7 Emcure Pharmaceuticals Ltd.
11.8 Hospira, Inc.
11.9 Lg Life Sciences Ltd.
11.1 Merck Kgaa
11.11 Mylan, Inc.
11.12 Ranbaxy Laboratories Ltd.
11.13 Roche Holding Ltd.
11.14 Sandoz International GMBH (Division Of Novartis International Ag)
11.15 Stada Arzneimittel Ag
11.16 Synthon
11.17 Teva Pharmaceutical Industries Ltd.
11.18 Wockhardt Ltd.

*Details On Financials, Product & Services, Strategy, & Developments Might Not Be Captured In Case Of Unlisted Companies.

List Of Tables (80 Tables)

Table 1 Region-Specific Terminology Of Biosimilars
Table 2 Key Attractive Biologics Under Threat Of Patent Expiry, 2012-2018
Table 3 Key Alliances Of The Biosimilars Industry
Table 4 Global Biosimilars Market, By Product, 2011-2018 ($Million)
Table 5 Global Biosimilars Market: Recombinant Non-Glycosylated Proteins, By Product, 2011-2018 ($Million)
Table 6 Biologic Insulin Going Off-Patent, 2010-2015
Table 7 Biosimilars Market: Insulin, By Geography, 2011-2018 ($Million)
Table 8 Biosimilars Market: Recombinant Human Growth Hormone, By Geography, 2011-2018 ($Million)
Table 9 Biosimilars Market: Granulocyte Colony-Stimulating Factor, By Geography, 2011-2018 ($Million)
Table 10 Biosimilars Market: Interferon, By Geography, 2011-2018 ($Million)
Table 11 Global Biosimilars Market: Recombinant Glycosylated Proteins, By Product, 2011-2018 ($Million)
Table 12 Biosimilars Market: Erythropoietin, By Geography, 2011-2018 ($Million)
Table 13 Biologic Recombinant Monoclonal Antibodies Going Off-Patent, 2010-2019
Table 14 Biosimilars Market: Monoclonal Antibodies, By Geography, 2011-2018 ($Million)
Table 15 Biosimilars Market: Follitropin, By Geography, 2011-2018 ($Million)
Table 16 Global Biosimilars Market: Recombinant Peptides, By Product,2011-2018 ($Million)
Table 17 Biosimilars Market: Glucagon, By Geography, 2011-2018 ($Million)
Table 18 Biosimilars Market: Calcitonin, By Geography, 2011-2018 ($Million)
Table 19 Global Biosimilar Market, By Application, 2011-2018 ($Million)
Table 20 Biosimilars Drugs Used To Treat Cancer
Table 21 Oncology Biosimilars Market, By Geography, 2011-2018 ($Million)
Table 22 Biosimilars Drugs Used To Treat Blood Disorders
Table 23 Blood Disorders Biosimilars Market, By Geography, 2011-2018 ($Million)
Table 24 Biosimilars Drugs Used To Treat Chronic And Autoimmune Disorder
Table 25 Chronic And Autoimmune Disorders Biosimilars Market, By Geography, 2011-2018 ($Million)
Table 26 Growth Hormonal Disorder Biosimilars Market, By Geography, 2011-2018 ($Million)
Table 27 Biosimilars Drugs Used To Treat Infectious Diseases
Table 28 Infectious Diseases Biosimilars Market, By Geography, 2011-2018 ($Million)
Table 29 Biosimilars Drugs Used To Treat Various Other Diseases
Table 30 Biosimilars Manufacturing Strategies Of Leading Players
Table 31 Joint Ventures Of Cmos & Pharmaceutical Companies For Biosimilars
Table 32 Joint Ventures Of Cros & Pharmaceutical Companies For Biosimilars
Table 33 Global Biosimilars Market, By Geography, 2011-2018 ($Million)
Table 34 Biosimilar Drugs In North America
Table 35 Biologic Drugs Going Off-Patent In The U.S., 2012-2018
Table 36 Regulatory Status In North America
Table 37 North America: Biosimilars Market, By Product, 2011-2018 ($Million)
Table 38 North America: Recombinant Non-Glycosylated Protein Market, By Product, 2011-2018 ($Million)
Table 39 North America: Recombinant Peptides Market, By Product, 2011-2018 ($Million)
Table 40 North America: Biosimilars Market, By Application, 2011-2018 ($Million)
Table 41 North America: Biosimilars Market, By Country, 2011-2018 ($Million)
Table 42 North America:Recombinant Non-Glycosylated Market, By Country, 2011-2018 ($Million)
Table 43 North America: Recombinant Peptides Market, By Country, 2011-2018 ($Million)
Table 44 Biosimilars Drugs In The European Market
Table 45 Biologic Drugs Going Off-Patent, 2013-2018
Table 46 Substitution Status In European Coutries
Table 47 Europe: Biosimilars Markets, By Product, 2011-2018 ($Million)
Table 48 Europe: Recombinant Non-Glycosylated Protein Market, By Product, 2011-2018 ($Million)
Table 49 Europe: Recombinant Glycosylated Protein Market, By Product, 2011-2018 ($Million)
Table 50 Europe: Recombinant Peptides Market, By Product, 2011-2018 ($Million)
Table 51 Europe: Biosimilars Market, By Application, 2011-2018 ($Million)
Table 52 Europe: Biosimilars Market, By Country, 2011-2018 ($Million)
Table 53 Europe: Recombinant Non-Glycosylated Market, By Country, 2011-2018 ($Million)
Table 54 Europe: Recombinant Glycosylated Market, By Country, 2011-2018 ($Million)
Table 55 Europe: Recombinant Peptides Market, By Country, 2011-2018 ($Million)
Table 56 Similar Biologic Drugs In Asia-Pacific Region
Table 57 Status Of Regulatory Pathway In Asia-Pacific Region
Table 58 APAC: Biosimilars Market, By Product, 2011-2018 ($Million)
Table 59 APAC: Recombinant Non-Glycosylated Protein Market, By Product, 2011-2018 ($Million)
Table 60 APAC: Recombinant Glycosylated Protein Market, By Product, 2011-2018 ($Million)
Table 61 APAC: Recombinant Peptides Market, By Product, 2011-2018 ($Million)
Table 62 APAC: Biosimilars Market, By Application, 2011-2018 ($Million)
Table 63 APAC:Biosimilars Market, By Country, 2011-2018 ($Million)
Table 64 APAC: Recombinant Non-Glycosylated Market, By Country, 2011-2018 ($Million)
Table 65 APAC: Recombinant Glycosylated Market, By Country, 2011-2018 ($Million)
Table 66 APAC: Recombinant Peptide Market, By Country, 2011-2018 ($Million)
Table 67 Biosimilars Drugs In Row
Table 68 Regulatory Status In The Row Biosimilars Market
Table 69 Row: Biosimilars Market, By Product, 2011-2018 ($Million)
Table 70 Row: Recombinant Non-Glycosylated Protein Market, By Product, 2011-2018 ($Million)
Table 71 Row: Recombinant Glycosylated Protein Market, By Product, 2011-2018 ($Million)
Table 72 Row: Recombinant Peptides Market, By Product, 2011-2018 ($Million)
Table 73 Row: Biosimilars Market, By Application, 2011-2018 ($Million)
Table 74 ROW:Biosimilars Market, By Region, 2011-2018 ($Million)
Table 75 Row: Recombinant Non-Glycosylated Market, By Region, 2011-2018 ($Million)
Table 76 Row: Recombinant Glycosylated Market, By Region, 2011-2018 ($Million)
Table 77 Row: Recombinant Peptide Market, By Region, 2011-2018 ($Million)
Table 78 Acquisitions, 2011-2013
Table 79 New Product Launches, By Company, 2011-2013
Table 80 Regulatory Approvals, By Company, 2011-2013


List Of Figures (80 Figures)

Figure 1 Market Estimation & Data Triangluation For Biosimilars Market
Figure 2 Global Biosimilars Market Forecasting Model
Figure 3 Global Biosimilars Market Revenue, 2013-2018 ($Million)
Figure 4 Global Biosimilars Market, By Geography, 2013-2018 ($Million)
Figure 5 Comparison Of Biosimilars &. Biologics Markets, Geographic Share, 2013
Figure 6 Global Biosimilars Market, Revenue & Growth Rate, 2013-2018
Figure 7 Global Biosimilars Market Dynamics
Figure 8 Global Biosimilars Market, By Product, 2013-2018
Figure 9 Global Biosimilars Market, By Application, 2013-2018
Figure 10 Biosimilars Market: Geographic Analysis, 2013 ($Million)
Figure 11 Global Biosimilars Market Share Analysis, By Key Players, 2013
Figure 12 Evolution Of The Biosimilars Market, 2005-2013
Figure 13 Global Biosimilars Market Segmentation
Figure 14 Biosimilars Under Pipeline, By Player
Figure 15 Number Of Biosimilar Monoclonal Antibodies In The Pipeline, By Company
Figure 16 Biosimilars In Preclinical Stage
Figure 17 Biosimilars In Phase I Clinical Trial
Figure 18 Biosimilars In Phase Ii Clinical Trial
Figure 19 Biosimilars In Phase Iii Clinical Trial
Figure 20 Global Biosimilars Market: Research & Development Analysis
Figure 21 Global Biosimilars Market: Porter’s Five Forces Analysis
Figure 22 Global Biosimilars Market: Opportunity Matrix, By Product, 2013
Figure 23 Global Biosimilars Market, By Product, 2011-2018 ($Million)
Figure 24 Global Biosimilars Market: Recombinant Non-Glycosylated Protein Biosimilars, By Product, 2011-2018 ($Million)
Figure 25 Global Biosimilars Market: Recombinant Glycosylated Proteins, By Product, 2011-2018 ($Million)
Figure 26 Global Biosimilars Market: Recombinant Peptides, By Product,2011-2018 ($Million)
Figure 27 Global Biosimilars Services Market Share, 2013 Vs. 2018
Figure 28 Opportunity Matrix: Biosimilars Market, By Country, 2013
Figure 29 Key Growth Strategies, 2010-2013
Figure 30 Global Biosimilars Market Share Analysis, By Key Player, 2013
Figure 31 Agreements, Joint Ventures, Partnerships, & Collaborations, By Company, 2010-2013
Figure 32 Agreements, Joint Ventures, Partnerships, & Collaborations, 2010-2013
Figure 33 Acquisitions, By Company, 2011-2013
Figure 34 New Product Launches, 2011-2013
Figure 35 Approvals, 2011-2013
Figure 36 Actavis: Total Revenue ($Billion) & Operating Margin (%), 2010-2012
Figure 37 Actavis: Business Revenue Mix, 2012
Figure 38 Actavis: Market Strategy, 2011-2013
Figure 39 Amgen, Inc.: Total Revenue ($Billion), 2010-2012
Figure 40 Amgen, Inc.: Geographic Revenue Mix, 2012
Figure 41 Amgen, Inc.: Market Strategy, 2011-2013
Figure 42 Biocon Ltd.: Total Revenue ($Million) & Operating Margin (%), 2011-2013
Figure 43 Celltrion, Inc.: Total Revenue ($Million) & Operating Margin (%), 2010-2012
Figure 44 Celltrion:Market Strategy, 2011-2013
Figure 45 Cipla Ltd.: Total Revenue ($Billion), 2011-2013
Figure 46 Cipla Ltd.: Geographic Revenue Mix, 2012
Figure 47 Dr.Reddy’s Laboratories Ltd.: Total Revenue ($Billion) &Operating Margin (%), 2011-2013
Figure 48 Dr.Reddy’s Laboratories Ltd.: Business Revenue Mix, 2013
Figure 49 Dr.Reddy’s Laboratories Ltd.: Geographic Revenue Mix, 2013
Figure 50 Dr. Reddy’s Laboratories Ltd.: Market Strategy, 2011-2013
Figure 51 Hospira, Inc.: Total Revenue ($Million) & Operating Margin (%), 2010-2012
Figure 52 Hospira, Inc.: Segment Revenue Mix, 2012
Figure 53 Hospira, Inc.: Geography Revenue Mix, 2012
Figure 54 Hospira, Inc. Market Strategy, 2011-2013
Figure 55 Lg Life Sciences: Total Revenue ($Million) & Operating Margin (%), 2010-2012
Figure 56 Merck: Total Revenue ($Billion) &Operating Margin (%), 2010-2012
Figure 57 Merck: Business Revenue Mix, 2012
Figure 58 Merck: Geographic Revenue Mix, 2012
Figure 59 Mylan, Inc.: Total Revenue ($Billion) & Operating Margin (%), 2010-2012
Figure 60 Mylan Inc.: Business Revenue Mix, 2012
Figure 61 Mylan Inc.: Geographic Revenue Mix, 2012
Figure 62 Mylan, Inc.: Market Strategy, 2011-2013
Figure 63 Ranbaxy Laboratories Ltd.: Total Revenue ($Billion) & Operating Margin (%), 2010-2012
Figure 64 Ranbaxy Laboratories Ltd.: Geographic Revenue Mix, 2011
Figure 65 Ranbaxy, Market Strategy, 2007-2013
Figure 66 Roche: Total Revenue ($Billion) & Operating Margin (%), 2010-2012
Figure 67 Roche: Business Revenue Mix, 2012
Figure 68 Roche: Geographic Revenue Mix, 2012
Figure 69 Sandoz International: Total Revenue ($Million) & Operating Margin (%), 2010-2012
Figure 70 Sandoz International: Segment Revenue Mix, 2012
Figure 71 Sandoz International: Geography Revenue Mix, 2012
Figure 72 Stada: Total Revenue ($Billion) & Operating Margin (%), 2010-2012
Figure 73 Stada: Business Revenue Mix, 2012
Figure 74 Stada: Geographic Revenue Mix, 2012
Figure 75 Teva Pharmaceutical Industries Ltd.: Total Revenue ($Million) & Operating Margin (%), 2010-2012
Figure 76 Teva Pharmaceutivcals Industrutries Ltd.: Segment Revenue Mix, 2012
Figure 77 Teva Pharmaceutical Industries Ltd.: Geographic Revenue Mix, 2012
Figure 78 Teva Pharmaceuticals Ltd.: Market Strategy, 2011-2013
Figure 79 Wockhardt: Total Revenue ($Billion) & Operating Margin (%), 2011-2013
Figure 80 Wockhardt: Geographic Revenue Mix, 2013

★調査レポート[世界のバイオシミラー市場予測] ( Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018 / MAM40116036) 販売に関する免責事項
[世界のバイオシミラー市場予測] ( Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018 / MAM40116036) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆